N-linked glycan compounds
US-9221898-B2 · Dec 29, 2015 · US
High purity heparin and production method therefor
US9540454B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9540454-B2 |
| Application number | US-201414565671-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 10, 2014 |
| Priority date | Sep 14, 2010 |
| Publication date | Jan 10, 2017 |
| Grant date | Jan 10, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides a high purity heparin useful to be a pharmaceutical product, cosmetics, research reagent, or the like, and a method for producing the same, more specifically, a heparin which does not substantially contain a nitrous acid degradation-resistant impurity and a method for producing a heparin, comprising mixing an aqueous solution of 5 to 30% by weight of the heparin with ethanol having an amount (volume) 0.2 to 1 times the amount (volume) of the aqueous heparin solution to obtain a colloidal precipitate of heparin.
First claim
Opening claim text (preview).
The invention claimed is: 1. A heparin obtainable by a method comprising mixing an aqueous solution of 5 to 30% by weight of a heparin with an organic solvent having an amount (volume) 0.2 to 1 times the amount (volume) of the aqueous heparin solution to obtain a colloidal precipitate of heparin, wherein the organic solvent is selected from ethanol, methanol, and a mixed solvent thereof, wherein a sodium chloride or sodium acetate salt is dissolved in a concentration of 50 to 500 mM in the aqueous heparin solution. 2. The heparin according to claim 1 , wherein the heparin has a molecular weight in a range of 3000 to 30000 dalton. 3. A method for producing a heparin, which comprises mixing an aqueous solution of 5 to 30% by weight of a heparin with an organic solvent having an amount (volume) 0.2 to 1 times the amount (volume) of the aqueous heparin solution to obtain a colloidal precipitate of heparin, wherein the organic solvent is selected from ethanol, methanol, and a mixed solvent thereof, wherein a sodium chloride or sodium acetate salt is dissolved in a concentration of 50 to 500 mM in the aqueous heparin solution. 4. A heparin obtainable by a method comprising mixing an aqueous solution of 5 to 30% by weight of a heparin with an organic solvent having an amount (volume) 0.2 to 1 times the amount (volume) of the aqueous heparin solution to obtain a supernatant fluid containing heparin, wherein the organic solvent is selected from ethanol, methanol, and a mixed solvent thereof, wherein a sodium chloride or sodium acetate salt is dissolved in a concentration of 50 to 5 mM in the aqueous heparin solution. 5. The heparin according to claim 4 , wherein the heparin has a molecular weight in a range of 1500 to 12000 dalton. 6. A method for producing a heparin, which comprises mixing an aqueous solution of 5 to 30% by weight of a heparin with an organic solvent having an amount (volume) 0.2 to 1 times the amount (volume) of the aqueous heparin solution to obtain a supernatant fluid containing heparin, wherein the organic solvent is selected from ethanol, methanol, and a mixed solvent thereof, wherein a sodium chloride or sodium acetate salt is dissolved in a concentration of 50 to 500 mM in the aqueous heparin solution. 7. The method according to claim 3 , wherein the heparin has a molecular weight in a range of 3000 to 30000 dalton. 8. The method according to claim 6 , wherein the heparin has a molecular weight in a range of 1500 to 12000 dalton.
Assignees
Inventors
Classifications
Immunosuppressants, e.g. drugs for graft rejection · CPC title
specific for metastasis · CPC title
Antihypertensives · CPC title
Drugs for disorders of the cardiovascular system · CPC title
Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9540454B2 cover?
- The present invention provides a high purity heparin useful to be a pharmaceutical product, cosmetics, research reagent, or the like, and a method for producing the same, more specifically, a heparin which does not substantially contain a nitrous acid degradation-resistant impurity and a method for producing a heparin, comprising mixing an aqueous solution of 5 to 30% by weight of the heparin w…
- Who is the assignee on this patent?
- Univ Miyazaki, Fuso Pharmaceutical Ind
- What technology area does this patent fall under?
- Primary CPC classification C08B37/00. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).